Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA clears IND for phase I study of MGD-007 for colorectal cancer

July 28, 2014

First patient treated in phase I study of MVA-BN Brachyury in advanced cancer

July 28, 2014

Enrollment complete in phase II trial of lirilumab in AML

July 25, 2014

Advaxis and MedImmune partner on immunotherapy combination trial

July 24, 2014

Biosceptre reports phase I results for BIL-010t in basal cell carcinoma

July 24, 2014

FDA grants breakthrough therapy designation to Aduro's pancreatic cancer combination immunotherapy

July 22, 2014

Mymetics to manufacture Imugene's HER-Vaxx cancer immunotherapy

July 17, 2014

Bristol-Myers Squibb plans Q3 BLA for Opdivo in advanced melanoma

July 11, 2014

Genmab achieves third milestone in daratumumab collaboration

July 9, 2014

Promising phase I data presented for a number of oncolytic immunotherapy candidates

July 8, 2014

Popular Stories

Today's news in brief
BioWorld
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...